Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad Genetics set to launch CardiaRisk genetic test for high blood pressure in January.

This article was originally published in The Gray Sheet

Executive Summary

MYRIAD GENETICS' CARDIARISK GENETIC HIGH BLOOD PRESSURE TEST LAUNCH is on track for mid-January, according to the company. Used to identify patients with hypertension who have a genetic variant that makes them particularly sensitive to sodium and who are at risk of heart disease, kidney failure and stroke, the test will be marketed to physicians via an outside sales force at a price of $300-400, the firm says.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009201

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel